Aeglea BioTherapeutics presented 20-dose data on 14 patients from the company's completed Phase 1/2 trial and ongoing Phase 2 open-label extension, or OLE, trial for pegzilarginase in patients with Arginase 1
Deficiency, or ARG1-D, at the Symposium of the Society for the Study of Inborn Errors of Metabolism, or SSIEM.
Aeglea Bio Therapeutics Inc (NASDAQ: AGLE): Phase 1/2, 20-week repeat dose data for pegzilarginase in arginase 1
ENPNewswire-August 30, 2019--Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1
Deficiency at 2019 SSIEM Symposium
Newer immunomarkers of hepatocellular Differentiation, such as arginase 1
and glypican 3, have been successfully used in hepatoid carcinoma of other organs (pancreas, adrenal, lung, and stomach).
Additionally, the expression of the following four macrophage polarization markers transglutaminase 2 (Tgm2), arginase 1
(Arg1), chemokine (C-X-C motif) ligand 9 (Cxcl9), and nitric oxide synthase 2 (Nos2) was also assessed (example gating schema in Supplementary Figure 8).
It also inhibits the expression of inducible nitric oxide synthase and stimulates the expression of arginase 1
, thereby preventing reactive nitric oxide production .
Unlike iNOS-mediated catabolism of arginine to NO in M1-like activated macrophages, M2-like activated macrophages catalyze arginine to urea and ornithine by arginase 1
(ARG1); ARG1 is a representative marker for M2-like activation.
He first encountered a patient with arginase 1
deficiency in 1972 and decided to make it the focus of his professional career.
However, the mRNA levels of OTC were extremely low in the non-AD subjects, and the normal cytoplasmic urea cycle enzyme arginase 1
(ARG1) was extremely low in both populations.
Target gene Primer sequence TNF [alpha] F: 5'-TTCTGTCTACTGAACTTCGGGGTGATCGGTCC-3' R: 5'-GTATGAGATAGCAAATCGGCTGACGGTGTGGG-3' Fizz1 F: 5'-TGGAGAATAAGGTCAAGGAAC-3' R: 5'-GTCAACGAGTAAGCACAGG-3' YM1 F: 5'-CATTCAGTCAGTTAT CAGATTCC-3' R: 5'-AGTGAGTAGCAGCCTTGG-3' iNOS F: 5'-GGCAGCCTGTGAGACCTTTG-3' R: 5'-GCATTGGAAGTGAAGCGTTTC-3' Arginase 1
F: 5'-AGACAGCAGAGGAGGTGAAGAG-3' R: 5'-CGAAGCAAGCCAAGGTTAAAGC-3' MMR F: 5'-AGTGGCAGGTGGCTTATG-3' R: 5'-GGTTCAGGAGTTGTTGTG-3' GAPDH F: 5'-ACCCAGAAGACTGTGGATGG-3' R: 5'-CACATTGGGGGTAGGAACAC-3' F, forward; R, reverse.
MDSCs can adopt multiple mechanisms to induce immunosuppression, including production of arginase 1
and inducible nitric oxide synthase, leading to T-cell inhibition [19,20].
In contrast, M2 microglia have an antiinflammatory phenotype, and express different molecules such as IL-4, arginase 1
, Ym1, CD163, CD206, and IL10.